Pulse Biosciences (NASDAQ: PLSE) hits 164-patient AF study enrollment target

What happened

Pulse Biosciences, Inc. (NASDAQ: PLSE) said its NANOPULSE-AF study reached its enrollment target of 164 evaluable patients. The study is a prospective, multicenter, non-randomized IDE pivotal clinical investigation of the nPulse Cardiac Catheter System in patients with drug-resistant, symptomatic, paroxysmal atrial fibrillation.

The company said the trial enrolled across 15 clinical sites, with the first patients treated in April 2026. Primary safety and effectiveness endpoints are due at 6 and 12 months post-ablation. The press release said target enrollment came three months ahead of the company's original 9-month timeline.

Key numbers

Metric	Latest	Change	Source
Enrollment target	164 evaluable patients		SEC 8-K
Clinical sites	15 clinical sites		SEC 8-K
Primary endpoints	6 and 12 months post-ablation		SEC 8-K

Read more: Pulse Biosciences (PLSE) stock analysis and investment case

Why it matters

OptimistFi's case is that Pulse Biosciences works only if patented Nano-pulse Stimulation becomes a clinically differentiated ablation platform before cash burn and dilution overwhelm the option value. This filing helps that case by showing the study moved from setup to full enrollment, which gives investors a clearer checkpoint on the nPulse Cardiac Catheter System.

Using the original 9-month timeline and the company's three-month lead, OptimistFi calculates the target was reached about 6 months after study start. That is a real execution step for a development-stage device program, and it reduces the risk that recruitment itself slows the study.

It still does not answer the main clinical question, because the filing reports no safety or effectiveness results. The target matters because the later endpoints can only be read after enough patients are in the study. For investors, that means the filing changes the watchlist more than the verdict. Primary safety and effectiveness endpoints are still scheduled for 6 and 12 months post-ablation.

Related: Pulse Biosciences, Inc. (NASDAQ: PLSE) Lines Up Cash for Its Next Clinical Tests

What's next

The next scheduled step is the primary safety and effectiveness assessment at 6 and 12 months post-ablation. Those later readouts will matter most for whether the nPulse Cardiac Catheter System looks clinically differentiated.

The company also said it expects to provide additional updates as patients complete follow-up. If the endpoint data are positive, the enrollment milestone becomes more valuable. If the data are weak or mixed, this filing remains an enrollment update rather than evidence of clinical performance.

More from OptimistFi